Vol 15, No 2 (February 28, 2026): Translational Lung Cancer Research

Original Article

Predictive modeling of immunotherapy efficacy in driver gene-negative non-small cell lung cancer
Xipeng Tao, Yufang Chen, Yumo Zhong, Xia Liu, Guangqin Zou, Xiangdong Zhou, Hu Luo
Translational Lung Cancer Research  
2026;
15
(2)
:24
.
PKC-iota drives EGFR-TKI resistance in EGFR-mutated NSCLC by phosphorylating FASN to reprogram lipid metabolism
Lin Ma, Yingwen Han, Lunran Xu, Qingyuan Sun, Siyue Song, Huizhen Yang, Xinran Chen, Wenhui Xie, Yumei Chen, Liu Liu
Translational Lung Cancer Research  
2026;
15
(2)
:25
.
Targeting NLRP3 inflammasome: a novel strategy for improving immune checkpoint inhibitor-associated pneumonitis
Shu-Yan Xiao, Yin-Min Ji, Yan Liu, Ya-Hui Lv, Yi Dong, Mei-Cen Liu, Yi-Heng Lu, Peng-Fei Cui, Tao Li, Xiao-Ran Cui, Yi Hu
Translational Lung Cancer Research  
2026;
15
(2)
:26
.
Analysis of clinical and genomic features in a Chinese cohort with NRG1 variations: a retrospective study
Meng Zhang, Yi Feng, Xue Du, Changda Qu, Meizhu Meng, Meiying Ye, Min Liang, Ziran Yang, Wenjuan Gong, Xingyu Ma, Jialiang Guo, Wenmei Li, Shuqin Jia
Translational Lung Cancer Research  
2026;
15
(2)
:27
.
Higher proximity of PD-L1+ tumor cells to PD-1+ tissue-resident memory CD8 determines response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Yimin Zhao, Yushan Yan, Liying Yang, Miaoqing Zhao, Hongtu Yuan, Jiaxiao Geng, Li Wu, Hao Yang, Qianhui Chen, Fanghan Cao, Ligang Xing, Xiaorong Sun
Translational Lung Cancer Research  
2026;
15
(2)
:28
.
Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis
Erick Suazo-Zepeda, Marjolein A. Heuvelmans, Douwe Postmus, T. Jeroen N. Hiltermann, Alain R. Viddeleer, Geertruida H. de Bock
Translational Lung Cancer Research  
2026;
15
(2)
:29
.
Correlation analysis between growth heterogeneity and genetic mutations in resected subsolid lung adenocarcinoma based on long-term computed tomography (CT) follow-up
Shulei Cui, Linlin Qi, Fenglan Li, Jia Jia, Jiaqi Chen, Sainan Cheng, Jianming Ying, Jianwei Wang
Translational Lung Cancer Research  
2026;
15
(2)
:30
.
Impact of baseline brain metastases on survival and CNS progression in NSCLC patients treated with immune checkpoint inhibitors in real-world studies: a systematic review and meta-analysis
William J. Shelton, Andrew P. Mathews, Eric R. Siegel, Analiz Rodriguez
Translational Lung Cancer Research  
2026;
15
(2)
:31
.
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation
Ying Lin, Ke Gong, Jingjing Wu, Chenchen Wei, Bo Yu, Zhihuang Hu, Yao Zhang, Zhenhua Wu, Xinmin Zhao, Hui Yu, Xianghua Wu, Jialei Wang, Xi Yang, Huijie Wang
Translational Lung Cancer Research  
2026;
15
(2)
:32
.
Real-world insights into multidisciplinary management and outcomes of stage III (N2–3) non-small cell lung cancer
Jing-Sheng Cai, Jia-Qi Zhao, Dilimulati Abulizi, Jie-Tian Jin, Si-Qing Liu, Mu-Zi Yang, Mao-Lin Liu, Hao-Xian Yang, Xue Hou
Translational Lung Cancer Research  
2026;
15
(2)
:33
.
Psychological distress in patients with detected pulmonary nodules from lung cancer screening
Jiani Chen, Yue Pan, Danxia Huang, Hengrui Liang, Wei Shen, Wenbiao Zou, Hao Liu, Sangchoon Jeon, Run Li, Ying Chen, Zengjie Ye, M. Tish Knobf, Ying Zhou, Jianxing He
Translational Lung Cancer Research  
2026;
15
(2)
:34
.
A radiomics-based nomogram for preoperatively predicting the invasiveness of nodular lung adenocarcinoma: a multicenter study
Xiaocui Liu, Xiuying Yang, Xiaofei Yue, Bo Sun, Jiayun Liu, Guilin Zhang, Jing Li, Chuansheng Zheng, Xuefeng Kan
Translational Lung Cancer Research  
2026;
15
(2)
:35
.
Molecular epidemiology and outcomes of EGFR exon 20 insertion in Korean patients with non-small cell lung cancer
Shinkyo Yoon, Seong-Eun Kim, Sun Min Lim, Hyun Ae Jung, Kyu-Pyo Kim, Dong-Kyu Kim, Hyehyun Jeong, Subin Lim, Jung-Ae Kim, Joohyun Kim, Dony Patel, Xiahong Zhao, Dae Young Yu, Ji Hyun Kim, Dae Ho Lee
Translational Lung Cancer Research  
2026;
15
(2)
:36
.
Multi-omics profiling reveals CDKN2A mutant early-onset lung squamous cell carcinoma with a “hot” tumor immune microenvironment
Ying Zhang, Pei Yuan, Bingzhi Wang, Lina Gao, Bingning Wang, Xin Hao, Lei Guo, Jianming Ying
Translational Lung Cancer Research  
2026;
15
(2)
:37
.
Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis
Ting Wang, Kai-Li Huang, Dan Pu, Ting Mei, Ming-Yu Fan, Long Tian, Lu Li, Xiao-Jun Tang, Qing-Hua Zhou
Translational Lung Cancer Research  
2026;
15
(2)
:38
.

Review Article

Current advances in mediastinal staging for non-small cell lung cancer: a narrative review
Fabrizio Minervini, Hannes Grünig, Peter Kestenholz, Thomas Gaisl, Savvas Lampridis
Translational Lung Cancer Research  
2026;
15
(2)
:40
.

Case Report

Pathological complete response following neoadjuvant chemoimmunotherapy in cancer of unknown primary: a case report
Ying-Long Peng, Hong-Yi Zhu, Hui-Bing Gao
Translational Lung Cancer Research  
2026;
15
(2)
:41
.
Discovery of a novel ITPR2::KRAS fusion in large cell neuroendocrine lung cancer: a case report
Anthony J. Patregnani, Rejowana Rouf, David R. Moline, Gabriella von Dohlen, Allison Makovec, Pawel Mroz, Andrew C. Nelson, Justin Hwang, Robert A. Kratzke
Translational Lung Cancer Research  
2026;
15
(2)
:42
.
Convex-probe endobronchial ultrasound-guided cryobiopsy for pleural tumors: three case reports
Toshiyuki Nakai, Yuichiro Furukawa, Hiroaki Nagamine, Shigeki Kakuno, Koichi Ogawa, Yoshiya Matsumoto, Kazuhiro Yamada, Tetsuya Watanabe, Kazuhisa Asai, Tatsuo Kimura, Takahiro Okuno, Tomoya Kawaguchi
Translational Lung Cancer Research  
2026;
15
(2)
:43
.

Letter to the Editor

A new therapeutic approach to KRAS mutant non-small cell lung cancer: the emerging role of exportin 1 inhibition
Mitchell S. von Itzstein, David E. Gerber
Translational Lung Cancer Research  
2026;
15
(2)
:44
.
Osimertinib opens the door for patients with EGFR-mutated advanced non-small cell lung cancer and a poor performance status: comment on the OPEN/TORG2040 trial
Tomoya Fukui, Katsuhiko Naoki
Translational Lung Cancer Research  
2026;
15
(2)
:45
.